Likang Life Sciences

Create more accurate and

powerful immune weapons for fighting cancer

To view more

History of immunology and tumor immunity

1893

Use of live bacteria and bacterial lysates to treat tumors-"Coley's Toxins" (William B. Coley).

History of immunology and tumor immunity

1957

Thomas and Burnet first proposed the theory of cancer immunosurveillance.

History of immunology and tumor immunity

1958

Discovery of human leukocyte antigens (Jean Dausset and others).

History of immunology and tumor immunity

1959

Discovery of antibody structure (independently elucidated by Gerald Edelman and Rodney Porter).

History of immunology and tumor immunity

1973

Dendritic Cells first described by Ralph M. Steinman.

History of immunology and tumor immunity

1974

T-cell restriction to MHC (Rolf Zinkernagel and (Peter C. Doherty)

History of immunology and tumor immunity

1975

Generation of monoclonal antibodies (Georges Köhler) and (César Milstein).

History of immunology and tumor immunity

1976

Identification of somatic recombination of immunoglobulin genes (Susumu Tonegawa)

History of immunology and tumor immunity

1983

Discovery of the T cell antigen receptor TCR (Ellis Reinherz) (Philippa Marrack) and (John Kappler) (James Allison)

History of immunology and tumor immunity

1985

Large doses of IL-2 were shown to be effective when administered to patients with established, metastatic cancers by enhancing T-cell production.

History of immunology and tumor immunity

1988

Autologous TIL used to treat melanoma patients.

History of immunology and tumor immunity

1992

Honjo first identified PD-1 as an inducible gene on activated T-lymphocytes, and this discovery significantly contributed to the establishment of cancer immunotherapy principle by PD-1 blockade.

History of immunology and tumor immunity

1995

First Dendritic cell vaccine trial reported by Mukherji et al.

History of immunology and tumor immunity

1996

James Allison was the first to show that antibody blockade of CTLA-4 could lead to enhanced anti-tumor immune responses and tumor rejection.

History of immunology and tumor immunity

1997

First antibody treatment approved for use by the FDA(rituximab).

History of immunology and tumor immunity

2010

The first autologous cell-based cancer vaccine, PROVENGE, is approved by the FDA for the treatment of metastatic, asymptomatic stage IV prostate cancer.

History of immunology and tumor immunity

2011

First immune checkpoint inhibitor, ipilimumab (anti-CTLA-4), is approved by the FDA.

History of immunology and tumor immunity

2014

A second class of immune checkpoint inhibitor (anti-PD-1) is approved by the FDA for the treatment of melanoma.

History of immunology and tumor immunity

2017

The first autologous CAR T-cell therapy Kymriah is approved for the treatment of pediatric B-ALL.

Two independent clinical studies provided solid evidence that neoantigen-based cancer vaccines could be developed to elicit potent neoantigen-specific T ce

1893
1957
1958
1959
1973
1974
1975
1976
1983
1985
1988
1992
1995
1996
1997
2010
2011
2014
2017

Scientific Platform

In personalized tumor immunotherapy, appropriate drug forms are selected for clinical treatment according to different indications based on the identification and screening of tumor-specific neoantigens. We developed Likang Neoantigen Epitope Analysis (LNEA) platform and dendritic cell (DC) loaded with tumor-specific neoantigens, neoantigen specific T cell (Neo-T), transgenic T cell (TCR-T), and etc. which may enable us to predict the presence of unique neoantigens in tumor cells of patients, and based on multiple product lines, gradually promote individualized tumor immunotherapy to clinical application.

To view more

A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma

To view more

A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for t

Because surgery and ablation can not completely remove cancer cells in patients, and liver cancer is not sensitive to traditional radiotherapy and chemotherapy, it is always a medical problem for patients to relapse and metastasis after local treatment such as ablation. According to statistics, after 5 years of local treatment, the recurrence rate of liver cancer is as high as 60-70%. In recent 10 years, tumor immunotherapy has become a promising treatment method because of its advantages in delaying tumor progression and protecting patients'anti-tumor immune function. Ralph Steinman won the Nobel Prize in Physiology or Medicine on October 3, 2011 for "the first discovery of dendritic cells in the immune system and their unique activation and regulation in acquired immunity"; on December 20, 2013, "Cancer Immunotherapy" was listed as the year of Science. The first breakthrough in science. On October 1, 2018, two immunologists, James Allison of the United States and Yasumoto of Japan, won the Nobel Prize in Physiology or Medicine for their contribution to the discovery of negative immunomodulation therapy for cancer. Cellular immunotherapy can eliminate the immunosuppressive state caused by tumors, activate the immune system of the body directly killing the immune cells of tumor cells, and completely remove the small lesions and residual tumor cells in the body of cancer patients. The treatment method is safe and effective. In 2009, autologous cell immunotherapy technology was listed in the first category III medical technology catalogue which was released by the Ministry of Health to allow clinical application.